Details of the Drug

General Information of Drug (ID: DMYZ57N)

Drug Name

Albendazole

Synonyms

Albendazol; Albendazolum; Albendoral; Albenza; Bendapar; Bilutac; Digezanol; Disthelm; Endoplus; Eskazole; Gascop; Lurdex; Metiazol; Proftril; Valbazen; Zental; Zentel; Albendazole Armstrong Brand; Albendazole Diba Brand; Albendazole Fustery Brand; Albendazole Hormona Brand; Albendazole Liferpal Brand; Albendazole Monohydrochloride; Albendazole Pfizer Brand; Albendazole Sanicoopa Brand; Albendazole Valdecasas Brand; Armstrong Brand of Albendazole; Diba Brand of Albendazole; Fustery Brand of Albendazole; Hormona Brand of Albendazole; Liferpal Brand of Albendazole; Mediamix V Disthelm; Noe Socopharm Brand of Albendazole; Pfizer Brand of Albendazole; Sanicoopa Brand of Albendazole; SmithKline Beecham Brand of Albendazole; Valdecasas Brand of Albendazole; SKF 62979; SKF62979; Albendazol [INN-Spanish]; Albendazole Noe-Socopharm Brand; Albendazolum [INN-Latin]; Albenza (TN); Disthelm, Mediamix V; Eskazole (TN); Monohydrochloride, Albendazole; Noe-Socopharm Brand of Albendazole; SK&F 62979; SK&F62979; SKF-62979; Smith Kline & French Brand of Albendazole; V Disthelm, Mediamix; Zentel (TN); SK&F-62979; Albendazole (JAN/USP/INN); Albendazole [USAN:INN:BAN:JAN]; Albenza, Eskazole, Zentel, Andazol, Albendazole; Methyl 5-(propylthio)-2-benzimidazolecarbamate; Methyl [5-(Propylthio)benzimidazol-2-yl]carbamate; Methyl-5-[propylthio]-2-benzimidazole carbamate; [5-(Propylthio)benzimidazol-2-yl]carbamic Acid Methyl Ester; Methyl 5-(propyl-thio)-2-benzimidazolecarbamate; Methyl [5-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate; Methyl [5-(propylthio)-1H-benzimidazol-2-yl]carbamate; Methyl [6-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate; [5-(Propythio)-1H-benzimidazol-2-yl]carbamic acid methyl ester; MethylN-(6-propylsulfanyl-1H-benzimidazol-2-yl)carbamate; O-Methyl N-(5-(propylthio)-2-benzimidazolyl)carbamate; Carbamic acid, [5-(propylthio)-1H-benzimidazol-2-yl]-, methyl ester; Methyl N-[6-(propylsulfanyl)-1H-1,3-benzodiazol-2-yl]carbamate; CARBAMIC ACID, (5-(PROPYLTHIO)-1H-BENZIMIDAZOL-2-YL)-, METHYL ESTER; Methyl [(2Z)-5-(propylsulfanyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]carbamate; ((Propylthio)-5 1H-benzimidazolyl-2) carbamate de methyle; ((Propylthio)-5 1H-benzimidazolyl-2) carbamate de methyle [French]; (5-(Propylthio)-1H-benzimidazol-2-yl)carbamic acid methyl ester; (5-Propylsulfanyl-1H-benzoimidazol-2-yl)-carbamic acid methyl ester; 5-(Propylthio)-2-carbomethoxyaminobenzimidazole

Indication

Disease Entry	ICD 11	Status	REF
Echinococcus granulosus infectious disease	N.A.	Approved	[1]
Helminth infection	1F90.0	Approved	[1]
Worm infection	1F90.Z	Approved	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Antiprotozoal Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

265.33

Logarithm of the Partition Coefficient (xlogp)

2.9

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Elimination: 0% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 8 - 12 hours [4]
Metabolism: The drug is metabolized via the hepatic []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 56.53 micromolar/kg/day [5]

Chemical Identifiers

Formula: C12H15N3O2S
IUPAC Name: methyl N-(6-propylsulfanyl-1H-benzimidazol-2-yl)carbamate
Canonical SMILES: CCCSC1=CC2=C(C=C1)N=C(N2)NC(=O)OC
InChI: InChI=1S/C12H15N3O2S/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)
InChIKey: HXHWSAZORRCQMX-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 2082
ChEBI ID: CHEBI:16664
CAS Number: 54965-21-8
DrugBank ID: DB00518
TTD ID: D00KVO
VARIDT ID: DR01323
INTEDE ID: DR0055
ACDINA ID: D00015

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tubulin beta (TUBB)	TTYFKSZ	NOUNIPROTAC	Binder	[6]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[7]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[8]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[9]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
C-C motif chemokine 2 (CCL2)	OTAD2HEL	CCL2_HUMAN	Gene/Protein Processing	[11]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Gene/Protein Processing	[12]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Gene/Protein Processing	[10]
Cytochrome P450 1A2 (CYP1A2)	OTLLBX48	CP1A2_HUMAN	Gene/Protein Processing	[10]
Cytochrome P450 1B1 (CYP1B1)	OTYXFLSD	CP1B1_HUMAN	Gene/Protein Processing	[13]
Heat shock factor protein 1 (HSF1)	OTYNJ4KP	HSF1_HUMAN	Gene/Protein Processing	[14]
HLA class II histocompatibility antigen, DM beta chain (HLA-DMB)	OT17HGXJ	DMB_HUMAN	Gene/Protein Processing	[15]
Interleukin-6 receptor subunit alpha (IL6R)	OTCQL07Z	IL6RA_HUMAN	Gene/Protein Processing	[11]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Gene/Protein Processing	[11]
Microtubule-associated protein tau (MAPT)	OTMTP2Z7	TAU_HUMAN	Gene/Protein Processing	[16]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Albendazole (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Arn-509	DMT81LZ	Moderate	Increased metabolism of Albendazole caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[17]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Albendazole caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[18]
Voriconazole	DMAOL2S	Moderate	Decreased metabolism of Albendazole caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[19]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Albendazole caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[17]
Telithromycin	DMZ4P3A	Moderate	Decreased metabolism of Albendazole caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[20]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Albendazole caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[21]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Albendazole caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[22]
Levobupivacaine	DM783CH	Minor	Increased metabolism of Albendazole caused by Levobupivacaine mediated induction of CYP450 enzyme.	Corneal disease [9A76-9A78]	[23]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Albendazole caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[19]
Ivacaftor	DMZC1HS	Moderate	Decreased clearance of Albendazole due to the transporter inhibition by Ivacaftor.	Cystic fibrosis [CA25]	[24]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Albendazole caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[25]
Aprepitant	DM053KT	Moderate	Decreased metabolism of Albendazole caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[26]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Albendazole caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[27]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Albendazole caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[28]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Albendazole caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[29]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Albendazole caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[17]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Albendazole caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[30]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Albendazole caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[31]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Albendazole caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[32]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Albendazole caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[33]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Albendazole caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[34]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Albendazole caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[35]
Cobicistat	DM6L4H2	Moderate	Decreased clearance of Albendazole due to the transporter inhibition by Cobicistat.	Human immunodeficiency virus disease [1C60-1C62]	[36]
Efavirenz	DMC0GSJ	Moderate	Increased metabolism of Albendazole caused by Efavirenz mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[37]
Saquinavir	DMG814N	Moderate	Decreased metabolism of Albendazole caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[38]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Albendazole caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[39]
Amprenavir	DMLMXE0	Moderate	Decreased metabolism of Albendazole caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[35]
Conivaptan	DM1V329	Moderate	Decreased metabolism of Albendazole caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[40]
Tasimelteon	DMLOQ1V	Moderate	Increased metabolism of Albendazole caused by Tasimelteon mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[41]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Albendazole caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[42]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Albendazole caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[43]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Albendazole caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[17]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Albendazole caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[44]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Albendazole caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[45]
Arry-162	DM1P6FR	Moderate	Increased metabolism of Albendazole caused by Arry-162 mediated induction of CYP450 enzyme.	Melanoma [2C30]	[19]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Albendazole caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[17]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Albendazole caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[46]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Albendazole and Ocrelizumab.	Multiple sclerosis [8A40]	[47]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Albendazole caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[17]
Nilotinib	DM7HXWT	Moderate	Decreased clearance of Albendazole due to the transporter inhibition by Nilotinib.	Myeloproliferative neoplasm [2A20]	[48]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive myelosuppressive effects by the combination of Albendazole and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[49]
Modafinil	DMYILBE	Minor	Increased metabolism of Albendazole caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[50]
Entrectinib	DMMPTLH	Moderate	Decreased metabolism of Albendazole caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[51]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Albendazole caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[52]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Albendazole caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[53]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Albendazole caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[54]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Albendazole caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[55]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Albendazole caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[56]
Bosentan	DMIOGBU	Moderate	Increased metabolism of Albendazole caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[57]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Albendazole and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[58]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Albendazole caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[59]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Albendazole caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[17]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Albendazole caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[19]
Armodafinil	DMGB035	Minor	Increased metabolism of Albendazole caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[50]
LEE011	DMMX75K	Moderate	Decreased metabolism of Albendazole caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[60]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Albendazole caused by Pitolisant mediated induction of CYP450 enzyme.	Somnolence [MG42]	[17]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Albendazole caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[61]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Albendazole and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[58]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Albendazole and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[58]
Ganciclovir	DM1MBYQ	Moderate	Additive myelosuppressive effects by the combination of Albendazole and Ganciclovir.	Virus infection [1A24-1D9Z]	[19]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Albendazole and Valganciclovir.	Virus infection [1A24-1D9Z]	[19]
-----------


⏷ Show the Full List of 61 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
D&C red no. 30	E00456	3000709	Colorant
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sucralose	E00370	71485	Flavoring agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Saccharin sodium monohydrate	E00417	443755	Flavoring agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
--------------------


⏷ Show the Full List of 8 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Albendazole 200 mg tablet	200 mg	Chewable Tablet	Oral
Albendazole 200 mg tablet	200 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Albendazole FDA Label
2	Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40.
3	BDDCS applied to over 900 drugs
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Flubendazole interferes with a wide spectrum of cell homeostatic mechanisms in Echinococcus granulosus protoscoleces. Parasitol Int. 2009 Sep;58(3):270-7.
7	The anthelminthic agent albendazole does not interact with p-glycoprotein. Drug Metab Dispos. 2002 Apr;30(4):365-9.
8	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
9	Danazol inhibits cytochrome P450 2J2 activity in a substrate-independent manner. Drug Metab Dispos. 2015 Aug;43(8):1250-3.
10	Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
11	Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents. Leuk Res. 2010 Jul;34(7):917-24. doi: 10.1016/j.leukres.2009.12.002. Epub 2010 Feb 8.
12	Identification of environmental chemicals that activate p53 signaling after in vitro metabolic activation. Arch Toxicol. 2022 Jul;96(7):1975-1987. doi: 10.1007/s00204-022-03291-5. Epub 2022 Apr 18.
13	Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
14	A Gene Expression Biomarker Predicts Heat Shock Factor 1 Activation in a Gene Expression Compendium. Chem Res Toxicol. 2021 Jul 19;34(7):1721-1737. doi: 10.1021/acs.chemrestox.0c00510. Epub 2021 Jun 25.
15	Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
16	Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression. Mol Neurodegener. 2006 Jul 26;1:6. doi: 10.1186/1750-1326-1-6.
17	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
18	Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
19	Cerner Multum, Inc. "Australian Product Information.".
20	Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
21	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
22	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
23	Product Information. Chirocaine (levobupivacaine) Organon, West Orange, NJ.
24	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
25	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
26	Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
27	Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
28	Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
29	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
30	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
31	Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44. [PMID: 10600094]
32	Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
33	Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
34	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
35	Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
36	Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
37	Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
38	Product Information. Fortovase (saquinavir) Roche Laboratories, Nutley, NJ.
39	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
40	Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
41	Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
42	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
43	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
44	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
45	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
46	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
47	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
48	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
49	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
50	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
51	Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
52	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
53	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
54	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
55	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
56	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
57	Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
58	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
59	Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
60	DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
61	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.